JP5866342B2 - Method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate - Google Patents
Method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate Download PDFInfo
- Publication number
- JP5866342B2 JP5866342B2 JP2013508833A JP2013508833A JP5866342B2 JP 5866342 B2 JP5866342 B2 JP 5866342B2 JP 2013508833 A JP2013508833 A JP 2013508833A JP 2013508833 A JP2013508833 A JP 2013508833A JP 5866342 B2 JP5866342 B2 JP 5866342B2
- Authority
- JP
- Japan
- Prior art keywords
- loxoprofen sodium
- pulverizer
- sodium dihydrate
- fine powder
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 title claims description 80
- 239000000843 powder Substances 0.000 title claims description 73
- 229960004211 loxoprofen sodium dihydrate Drugs 0.000 title claims description 72
- 238000004519 manufacturing process Methods 0.000 title claims description 29
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 8
- 239000002245 particle Substances 0.000 claims description 73
- 238000010298 pulverizing process Methods 0.000 claims description 53
- 238000009826 distribution Methods 0.000 claims description 25
- 239000013078 crystal Substances 0.000 claims description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000000227 grinding Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 229960002373 loxoprofen Drugs 0.000 description 8
- 238000012545 processing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- 230000020169 heat generation Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000011802 pulverized particle Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Crushing And Pulverization Processes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は、ロキソプロフェンナトリウム二水和物の製剤用微粉末の製造方法に関するものであり、詳細には、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が20〜120μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末を高い生産性で製造する方法に関する。 The present invention relates to a method for producing a fine powder for preparation of loxoprofen sodium dihydrate, and more specifically, the volume average particle size is in the range of 20 to 120 μm when measured with a laser diffraction particle size distribution meter. The present invention relates to a method for producing a fine powder of loxoprofen sodium dihydrate with high productivity.
ロキソプロフェンナトリウム(一般名)(2−[4−(2−オキソシクロペンタン1−イルメチル)フェニル]プロピオン酸ナトリウム(化学名))は、非ステロイド性の消炎、鎮痛、及び解熱剤であり、慢性関節リウマチ、変形性関節症、腰痛等の治療に広く用いられている。 Loxoprofen sodium (generic name) (sodium 2- [4- (2-oxocyclopentan-1-ylmethyl) phenyl] propionate (chemical name)) is a non-steroidal anti-inflammatory, analgesic and antipyretic agent, and rheumatoid arthritis It is widely used for the treatment of osteoarthritis, low back pain, etc.
通常、薬品の製剤時に用いられる原薬の粉末は適当な粒子径にまで粉砕しておかなければならない。この理由としては、以下のi)〜iii)などが挙げられる。i)粒径を適当な大きさに揃えることで賦形剤等との均一な混合が容易になる。ii)錠剤等を成形する際に表面がきれいで滑らかに仕上がる。iii)有効成分の体内への吸収を一定に保つ。 Normally, the drug substance powder used in drug formulation must be ground to an appropriate particle size. Examples of this include the following i) to iii). i) Uniform mixing with excipients and the like is facilitated by adjusting the particle size to an appropriate size. ii) The surface is clean and smooth when molding tablets. iii) Keep the absorption of active ingredients in the body constant.
一般に、粉砕方式としては、乾式粉砕、湿式粉砕、凍結粉砕などがあるが、医薬品の粉砕においては乾式粉砕がコスト面等において最も適している。粉砕する際に利用する力としては、圧縮力(押しつぶし)、剪断力(カッター又はナイフによる切断)、衝撃力(高速回転するハンマ若しくはピン、又は粒子同士の衝突)、磨砕力(すりつぶし)などがあるが、医薬品の製剤に用いられる微粉末(通常、体積平均粒子径数μm〜数百μm)の製造には衝撃力を利用する粉砕機が適している。この種の粉砕機には以下に示す三種のものがありそれぞれに特徴がある。 In general, there are dry pulverization, wet pulverization, freeze pulverization and the like as pulverization methods, but dry pulverization is most suitable in terms of cost and the like for pharmaceutical pulverization. The force used for pulverization includes compression force (crushing), shearing force (cutting with a cutter or knife), impact force (high-speed rotating hammer or pin or collision between particles), grinding force (grinding), etc. However, a pulverizer using an impact force is suitable for producing fine powder (usually several μm to several hundred μm in volume average particle diameter) used in pharmaceutical preparations. This type of pulverizer has the following three types, each having its own characteristics.
1)ピンミル粉砕機:高速回転する本体側ディスクピン又はプレートビータ(プレート状ハンマ)と固定ドアー側のディスクピン間で微粉砕が行われる。ピンの数や回転速度等により、粒子径や粒度分布の調整が行われる。
2)ジェットミル粉砕機:ジェット気流粉砕機とも呼ばれる。ノズルから噴射される高圧の空気又は窒素ガスを超高速ジェットとして粒子に衝突させ、粒子同士の衝撃によって微粒子を得る。
3)気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機:ピンハンマ式粉砕ロータの回転と粉砕室内壁のライナ間の衝撃で粉砕する。分級ロータが装着されているので、一定の粒径まで粉砕された粒子は分級チェンバーに送られ、過粉砕を防ぐことができる。この種の粉砕機には、アトマイザーとほぼ同じ構造原理であるが、ハンマの数が少なく、ライニングとのギャップを大きくして大きな塊を処理するのに適したパルベライザ型粉砕機が含まれる。この種の粉砕機では分解・洗浄が容易である。1) Pin mill pulverizer: Fine pulverization is performed between a disk pin or plate beater (plate-shaped hammer) that rotates at high speed and a disk pin on the stationary door side. The particle size and particle size distribution are adjusted according to the number of pins and the rotation speed.
2) Jet mill pulverizer: Also called a jet air pulverizer. High-pressure air or nitrogen gas injected from a nozzle is caused to collide with particles as an ultrahigh-speed jet, and fine particles are obtained by impact between the particles.
3) Impact type pulverizer with a built-in airflow classifying mechanism and using a pin hammer: pulverization is performed by the rotation of the pin hammer type pulverizing rotor and the impact between the liners on the inner wall of the pulverizing chamber. Since the classification rotor is mounted, the particles pulverized to a certain particle size are sent to the classification chamber, and over-pulverization can be prevented. This type of pulverizer includes a pulverizer type pulverizer that has almost the same structural principle as the atomizer, but has a small number of hammers and is suitable for processing a large lump by increasing the gap with the lining. This kind of pulverizer is easy to disassemble and clean.
ロキソプロフェンナトリウムは、通常、二水和物の結晶性粉末であり、製剤時には体積平均粒子径が数十μm程度の微粉末が用いられることがある(特許文献1)。製剤に適した粒径は、レーザー回折式粒度分布計で測定するとき、通常、体積平均粒子径が20〜120μmの範囲にあることが好ましいとされている。 Loxoprofen sodium is usually a dihydrate crystalline powder, and a fine powder having a volume average particle size of about several tens of μm may be used in the preparation (Patent Document 1). When the particle size suitable for the preparation is measured with a laser diffraction particle size distribution analyzer, it is usually preferred that the volume average particle size is in the range of 20 to 120 μm.
しかしながら、特許文献1〜4に記載されているように、ロキソプロフェンナトリウム二水和物の粉末には、この物質に特有の付着性及び固着性があり、薬物同士や機器、容器等に付着・固着して著しく加工を妨げる性質があることがよく知られている。したがって、製剤原料として要求される粒子径や粒度分布にまでロキソプロフェンナトリウムを粉砕するには、ロキソプロフェンナトリウムの付着・固着による粉砕機の閉塞や、それに伴う摩擦熱による溶融等による品質の劣化を防ぐための特段の配慮が必要であり、生産性を犠牲にしてでもロキソプロフェンナトリウムの微粉末を製造せざるを得ない状況にある。
このように、粉砕時における粉砕機内部及び粉砕ユニットへのロキソプロフェンナトリウムの付着及び固着を回避して、ロキソプロフェンナトリウム微粉末を効率よく生産できる技術は、未だ確立されていない。However, as described in Patent Documents 1 to 4, loxoprofen sodium dihydrate powder has adhesion and adhesion specific to this substance, and adheres and adheres to drugs, devices, containers, etc. Thus, it is well known that it has the property of significantly hindering processing. Therefore, in order to grind loxoprofen sodium to the required particle size and particle size distribution as a raw material for preparation, to prevent clogging of the grinder due to adhesion and sticking of loxoprofen sodium and the resulting deterioration due to melting due to frictional heat, etc. In particular, loxoprofen sodium fine powder must be produced even at the expense of productivity.
Thus, a technique that can efficiently produce fine loxoprofen sodium powder while avoiding adhesion and fixation of loxoprofen sodium to the inside of the pulverizer and to the pulverization unit during pulverization has not yet been established.
製剤に用いられるロキソプロフェンナトリウム二水和物の結晶性微粉末を得るための粉砕操作は、本化合物の特性である付着・固着性により著しく妨げられ、生産性の低下を招く。本発明は、このような付着・固着特性に配慮した粉砕方法を適用することにより、ロキソプロフェンナトリウム二水和物の粉砕時における粉砕機内部及び粉砕ユニットへの該化合物の付着及び固着を回避して品質の劣化を防ぎ、所望の粒径及び粒度分布を有するロキソプロフェンナトリウム二水和物の微粉末を高い生産性のもとで得ことを課題とする。 The pulverization operation for obtaining a crystalline fine powder of loxoprofen sodium dihydrate used in the preparation is significantly hindered by the adhesion / sticking property which is a characteristic of the present compound, resulting in a decrease in productivity. The present invention avoids adhesion and fixation of the compound to the inside of the pulverizer and to the pulverization unit at the time of pulverization of loxoprofen sodium dihydrate by applying such a pulverization method considering the adhesion and adhesion characteristics. It is an object of the present invention to obtain a fine powder of loxoprofen sodium dihydrate having a desired particle size and particle size distribution while preventing deterioration of quality under high productivity.
本発明者は、上記課題に鑑み、鋭意研究し、種々の粉砕機を検討した結果、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機のみが上記目的に有用であることを見出し、本発明を完成させるに至った。また、ピンハンマを用いる衝撃式粉砕機の中でも、気流分級機構を内蔵するものが好適であり、中でもパルベライザ型粉砕機が特に好適であることを見出した。パルベライザ型粉砕機は、ダルトン株式会社、東京アトマイザー製造株式会社、ホソカワミクロン株式会社などより発売されている。すなわち、本発明は、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、好ましくは気流分級機構を内蔵するパルベライザ型粉砕機を用いることにより、ロキソプロフェンナトリウム二水和物微粉末作製時における、ロキソプロフェンナトリウム二水和物の付着・固着特性による生産性の低下を回避することを特徴とするものである。この方法により、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が20〜120μmの範囲にある粒子を効率よく連続生産できる。このような粒子径を有するロキソプロフェンナトリウム二水和物の微粒子は、各種医薬品製剤、中でも特に錠剤;クリーム剤や軟膏剤等の塗布剤;プラスター剤、テープ剤、パッチ剤、パップ剤等の貼付剤等の製造に適したものである。 As a result of diligent research and examination of various pulverizers, the present inventor has found that only an impact pulverizer that incorporates an airflow classification mechanism and uses a pin hammer is useful for the above purpose. The invention has been completed. Further, it has been found that among impact type pulverizers using a pin hammer, those equipped with an airflow classification mechanism are suitable, and among them, a pulverizer type pulverizer is particularly suitable. Pulverizer pulverizers are available from Dalton Co., Tokyo Atomizer Manufacturing Co., Ltd. and Hosokawa Micron Co., Ltd. That is, the present invention incorporates an airflow classification mechanism and uses an impact-type pulverizer using a pin hammer, preferably a pulverizer-type pulverizer with a built-in airflow classification mechanism, to produce loxoprofen sodium dihydrate fine powder, It is characterized by avoiding a decrease in productivity due to the adhesion and sticking properties of loxoprofen sodium dihydrate. By this method, when measuring with a laser diffraction particle size distribution meter, particles having a volume average particle diameter in the range of 20 to 120 μm can be efficiently and continuously produced. Loxoprofen sodium dihydrate fine particles having such a particle size are used in various pharmaceutical preparations, particularly tablets; coating agents such as creams and ointments; patches such as plasters, tapes, patches, and poultices. It is suitable for manufacturing such as.
以下に、検討した結果をより詳細に示す。
ロキソプロフェンナトリウム二水和物の結晶をピンミル粉砕機で粉砕しようとすると、粉砕時に粉砕ユニットであるピンへ微粉末が付着・固着しそれが成長することでピン間隔がしだいに狭くなり、短時間で閉塞に至り、摩擦熱により結晶が融解して粉砕不能になった。
ピンディスクのピンを間引くことで、ピン間隔を広げても状況は改善されなかった。ロキソプロフェンナトリウム二水和物は、通常58〜77℃で結晶水の脱離が起きるのでピンミル粉砕時には粉砕機への付着・固着−閉塞に伴う発熱により結晶水が脱離し組成が変化する。したがって、粉砕機へのロキソプロフェンナトリウム二水和物の供給量を増加させると製品の均一性が確保できないピンミル粉砕の使用は、ロキソプロフェンナトリウム二水和物微粉末の効率的な生産には不適当であると判断される。The results of the examination are shown in more detail below.
When trying to grind loxoprofen sodium dihydrate crystals with a pin mill grinder, the fine powder adheres to and adheres to the pin, which is the grinder unit, and grows. Occurrence of clogging caused the crystal to melt due to frictional heat, making it impossible to grind.
By thinning the pins of the pin disc, the situation was not improved even if the pin spacing was increased. Loxoprofen sodium dihydrate usually loses water of crystallization at 58 to 77 ° C., and therefore, during pin mill pulverization, the water of crystallization is desorbed due to heat generated due to adhesion / fixation / clogging to the pulverizer, and the composition changes. Therefore, the use of pin mill grinding, which cannot ensure product uniformity when increasing the amount of loxoprofen sodium dihydrate supplied to the grinder, is unsuitable for efficient production of loxoprofen sodium dihydrate fine powder. It is judged that there is.
次に、ロキソプロフェンナトリウム二水和物の結晶をジェットミル粉砕機で粉砕することを試みた。この場合、粉砕圧を最低レベルまで落とすと粉砕は可能であったが、粒度が細かくなりすぎ比容積が大きくなって製剤原料としては適さないものしか得られなかった。また、この粉砕機はその構造上、粉砕する前に他の解砕機(カッターミル等)であらかじめ前処理粉砕をしないと供給ノズルが閉塞するので生産性が低下する。また処理量が大きくなると、設備投資(バグフィルタ等)が他の粉砕機に比較して大きくなり、コンプレッサーを使用するため電力ランニングコストも大きくなる。したがって、ジェットミル粉砕機はロキソプロフェンナトリウム二水和物を効率よく粉砕する方法としては好適ではないことが分かった。 Next, an attempt was made to grind loxoprofen sodium dihydrate crystals with a jet mill grinder. In this case, although the pulverization was possible when the pulverization pressure was lowered to the lowest level, the particle size became too fine and the specific volume was increased, so that only a material suitable as a drug substance was obtained. In addition, due to the structure of this pulverizer, if the pretreatment pulverization is not performed in advance by another pulverizer (cutter mill or the like) before pulverization, the supply nozzle is blocked, so that productivity is lowered. In addition, when the amount of processing increases, the capital investment (such as a bag filter) increases compared to other pulverizers, and the use of a compressor increases the power running cost. Therefore, it was found that the jet mill grinder is not suitable as a method for efficiently grinding loxoprofen sodium dihydrate.
ロキソプロフェンナトリウム二水和物の微粉末の製造は上記のピンミル粉砕機やジェットミル粉砕機では生産性に問題があった。一方、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、とりわけ気流分級機構を内蔵するパルベライザ型粉砕機の使用を試みたところ、驚くべき改善がみられた。すなわち:
1)実生産を想定したロキソプロフェンナトリウム二水和物の粉砕機への単位時間当たりの供給量のもとで粉砕を行っても、微粉末の付着・固着による粉砕機の閉塞はみられなかった。
2)粉砕中に顕著な発熱はなく、冷却操作も必要なかった。これは、ロキソプロフェンナトリウム二水和物の付着・固着による粉砕機内部又は粉砕ロータ部への滞留がなかったためである。また、分級ロータを内蔵しているため、過粉砕が抑制されて、粉砕品の粒度分布がよりシャープになり、より製剤化しやすい微粉末を得ることができた。
3)分級ロータを内蔵しているので、前処理粉砕の必要はなく、粉砕品についてもさらに篩過する必要がなかった。したがって、生産性が大幅に改善された。
4)ランニングコストがピンミル粉砕機やジェットミル粉砕機に比べて最も安価であった。
5)以上より、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、とりわけ気流分級機構を内蔵するパルベライザ型粉砕機を用いるとロキソプロフェンナトリウム二水和物の微粉末の商業的な連続生産が可能であることが判明した。Production of fine powder of loxoprofen sodium dihydrate had a problem in productivity in the above-described pin mill grinder and jet mill grinder. On the other hand, when an attempt was made to use an impact-type pulverizer with a built-in airflow classification mechanism and a pin hammer, particularly a pulverizer-type pulverizer with a built-in airflow classification mechanism, a surprising improvement was observed. Ie:
1) No clogging of the crusher due to adhesion / adherence of fine powder was observed even when pulverization was performed under the supply amount per unit time of loxoprofen sodium dihydrate assuming actual production. .
2) There was no significant heat generation during pulverization, and no cooling operation was required. This is because loxoprofen sodium dihydrate did not stay in the pulverizer or in the pulverization rotor due to adhesion / fixation. Moreover, since the classification rotor was built in, overpulverization was suppressed, the particle size distribution of the pulverized product became sharper, and a fine powder that was easier to formulate could be obtained.
3) Since the classifying rotor is built-in, there is no need for pretreatment grinding, and the pulverized product does not need to be further sieved. Therefore, productivity has been greatly improved.
4) The running cost was the lowest compared with the pin mill and jet mill grinder.
5) From the above, commercial continuous production of fine powder of loxoprofen sodium dihydrate can be achieved by using an impact pulverizer with a built-in airflow classification mechanism and an impact pulverizer using a pin hammer, especially a pulverizer pulverizer with a built-in airflow classification mechanism. It turned out to be possible.
以上の結果をまとめると下記表1のようになる。ロキソプロフェンナトリウム二水和物の微粉末を、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、好ましくはパルベライザ型粉砕機により作製すると、他の粉砕機に比べて粉砕処理能力が飛躍的に向上し、粉砕の前処理及び後処理が必要なく生産性が大幅に向上することが明らかである。 The above results are summarized as shown in Table 1 below. When a fine powder of loxoprofen sodium dihydrate is built with an impact pulverizer with a built-in airflow classification mechanism and a pin hammer, preferably a pulverizer-type pulverizer, the pulverization ability is dramatically higher than other pulverizers. It is clear that productivity is greatly improved without the need for pre- and post-grinding treatments.
すなわち、本発明は、以下の(1)〜(4)に関する。
(1)ロキソプロフェンナトリウム二水和物の結晶又は結晶性の粉末を、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機を用いて粉砕し、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が20〜120μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末を連続して製造することを特徴とするロキソプロフェンナトリウム二水和物の医薬品製剤用微粉末の製造方法。
(2)気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機が、パルベライザ型粉砕機である前記(1)に記載の製造方法。
(3)ロキソプロフェンナトリウム二水和物の微粉末が、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が20〜120μmの範囲にあり、該ロキソプロフェンナトリウム二水和物の微粉末を一時間当たり40Kg以上連続して作製する前記(1)又は(2)に記載の製造方法。
(4)気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機による粉砕が、ピンハンマロータの回転速度6000〜9000rpm、かつ分級ロータの回転速度2000〜5000rpmの条件下行われる前記(1)〜(3)のいずれか一項に記載の製造方法。That is, the present invention relates to the following (1) to (4).
(1) When loxoprofen sodium dihydrate crystals or crystalline powders are pulverized using an impact pulverizer equipped with an airflow classification mechanism and using a pin hammer and measured with a laser diffraction particle size distribution meter A method for producing a fine powder of loxoprofen sodium dihydrate for pharmaceutical preparation, characterized by continuously producing a fine powder of loxoprofen sodium dihydrate having an average particle size in the range of 20 to 120 µm.
(2) The production method according to (1), wherein the impact type pulverizer having a built-in airflow classification mechanism and using a pin hammer is a pulverizer type pulverizer.
(3) When the fine powder of loxoprofen sodium dihydrate is measured with a laser diffraction particle size distribution meter, the volume average particle diameter is in the range of 20 to 120 μm, and the fine powder of loxoprofen sodium dihydrate is one The production method according to (1) or (2), wherein 40 Kg or more is continuously produced per hour.
(4) The above-mentioned (1) to (1), wherein the air pulverization mechanism is incorporated and the pulverization by the impact type pulverizer using the pin hammer is performed under the conditions of the rotational speed of the pin hammer rotor of 6000 to 9000 rpm and the rotational speed of the classification rotor of 2000 to 5000 rpm. The production method according to any one of 3).
本発明の方法によれば、ロキソプロフェンナトリウム二水和物の微粉末を得るための粉砕時における該化合物の粉砕機内部及び粉砕ユニットへの付着及び固着を回避することができるため、該微粉末の生産性を飛躍的に向上させることができる。本発明の方法によれば、各種製剤、特に錠剤;クリーム剤、軟膏剤等の塗布剤;プラスター剤、テープ剤、パッチ剤、パップ剤等の貼付剤等の製造に好適なロキソプロフェンナトリウム二水和物の微粉末を連続的に、効率よく製造することができる。 According to the method of the present invention, it is possible to avoid adhesion and sticking of the compound to the inside of the pulverizer and to the pulverizing unit at the time of pulverization to obtain fine powder of loxoprofen sodium dihydrate. Productivity can be dramatically improved. According to the method of the present invention, loxoprofen sodium dihydrate suitable for the production of various preparations, particularly tablets; coating agents such as creams and ointments; plasters, tapes, patches, patches, etc. A fine powder of a product can be produced continuously and efficiently.
本発明のロキソプロフェンナトリウム二水和物の医薬品製剤用微粉末の製造方法においては、ロキソプロフェンナトリウム二水和物の結晶又は結晶性の粉末を、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機を用いて粉砕し、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約20〜120μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末を連続して製造する。ロキソプロフェンナトリウム二水和物の結晶又は結晶性の粉末を、前記の衝撃式粉砕機を用いて粉砕することにより、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約20〜120μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末を連続して効率よく製造することができる。 In the method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate according to the present invention, an impact pulverizer using a pin hammer with a loxoprofen sodium dihydrate crystal or crystalline powder incorporated with an airflow classification mechanism Is used, and a fine powder of loxoprofen sodium dihydrate having a volume average particle size in the range of about 20 to 120 μm is continuously produced when measured with a laser diffraction particle size distribution analyzer. When loxoprofen sodium dihydrate crystals or crystalline powder is measured by a laser diffraction particle size distribution meter by pulverization using the above-mentioned impact pulverizer, the volume average particle size is about 20 to 120 μm. A fine powder of loxoprofen sodium dihydrate within the range can be produced continuously and efficiently.
ロキソプロフェンナトリウム二水和物の結晶及び結晶性の粉末は、例えば、J. Med. Chem., 1984, 27 (2), pp 212−216に記載の方法に従って製造することができる。 Loxoprofen sodium dihydrate crystals and crystalline powder can be produced, for example, according to the method described in J. Med. Chem., 1984, 27 (2), pp 212-216.
本発明においては、合成したロキソプロフェンナトリウム二水和物の結晶又は結晶性の粉末を、前処理粉砕することなくそのまま気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機に投入して粉砕に供することができる。 In the present invention, the synthesized loxoprofen sodium dihydrate crystals or crystalline powder is incorporated into an airflow classification mechanism as it is without being pre-processed and supplied to an impact type pulverizer using a pin hammer for pulverization. be able to.
本発明において使用される気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機は、好ましくは、パルベライザ型粉砕機である。このような粉砕機を使用すると、粉砕した粒子をさらに篩過する必要がない。このため、生産性がより大幅に向上する。気流分級機構を内蔵するパルベライザ型粉砕機は複数のメーカーから販売されており特に限定されないが、例えば、一時間あたりの処理能力(粉砕可能な原料量)が約40kg以上の装置が好ましい。 The impact type pulverizer incorporating the airflow classification mechanism used in the present invention and using a pin hammer is preferably a pulverizer type pulverizer. When such a pulverizer is used, it is not necessary to further sieve the pulverized particles. For this reason, productivity is significantly improved. The pulverizer type pulverizer having a built-in airflow classification mechanism is sold by a plurality of manufacturers and is not particularly limited. For example, an apparatus having a processing capacity per hour (a pulverizable raw material amount) of about 40 kg or more is preferable.
本発明の製造方法においては、前述したロキソプロフェンナトリウム二水和物の微粉末を、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、好ましくは、パルベライザ型粉砕機により一時間当たり約30Kg以上連続して製造することが好ましく、一時間当たり約40Kg以上連続して製造することがより好ましい。 In the production method of the present invention, the above-mentioned fine powder of loxoprofen sodium dihydrate is incorporated into an airflow classification mechanism, and is an impact pulverizer using a pin hammer, preferably about 30 kg or more per hour by a pulverizer pulverizer. It is preferable to produce continuously, and it is more preferred to produce continuously about 40 kg or more per hour.
気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機による粉砕の条件は、例えば、衝撃式粉砕機においてピンハンマロータの回転数、及び分級ロータの回転速度を調整することにより調整することができる。 The conditions of pulverization by an impact pulverizer that incorporates an airflow classification mechanism and uses a pin hammer can be adjusted, for example, by adjusting the rotational speed of the pin hammer rotor and the rotational speed of the classification rotor in the impact pulverizer. .
本発明においては、気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、例えばパルベライザ型粉砕機による粉砕は、ピンハンマロータの回転速度が約12000rpm以下で行われることが好ましい。すなわち、使用する衝撃式粉砕機、好ましくはパルベライザ型粉砕機のピンハンマロータの回転数をこのように設定することが好ましい。気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機による粉砕は、分級ロータの回転速度が約6000rpm以下の条件で行われることが好ましい。ピンハンマロータの回転速度及び分級ロータの回転速度をこのような範囲とすることにより、ロキソプロフェンナトリウム二水和物の粉砕機内部及び粉砕ユニットへの付着及び固着をより効果的に抑制でき、体積平均粒子径が20〜120μmの微粉末をより効率よく生産することができる。前記体積平均粒子径が20〜120μmのロキソプロフェンナトリウム二水和物の微粉末を、一時間当たり40Kg以上連続して作製する場合には、ピンハンマロータの回転最大速度及び分級ロータの最大回転速度を上記範囲とすることが好ましい。
気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機による粉砕においては、ピンハンマロータの回転は、下限が約4000rpm以上であることが好ましい。より好ましくは、ピンハンマロータの回転速度を約6000〜9000rpmとする。さらに、分級ロータの回転速度の下限は、約2000rpm以上であることが好ましい。分級ロータの回転速度は、より好ましくは約2000〜5000rpmである。In the present invention, pulverization by an impact pulverizer using a pin hammer, for example, a pulverizer pulverizer, is preferably performed at a rotational speed of the pin hammer rotor of about 12000 rpm or less. That is, it is preferable to set the rotational speed of the pin hammer rotor of the impact type pulverizer used, preferably the pulverizer type pulverizer, in this way. It is preferable that the pulverization by the impact pulverizer using the pin hammer with the airflow classification mechanism is performed under the condition that the rotational speed of the classification rotor is about 6000 rpm or less. By setting the rotational speed of the pin hammer rotor and the rotational speed of the classification rotor within such ranges, adhesion and sticking of loxoprofen sodium dihydrate to the inside of the grinding machine and to the grinding unit can be more effectively suppressed. A fine powder having a particle size of 20 to 120 μm can be produced more efficiently. When the loxoprofen sodium dihydrate fine powder having a volume average particle size of 20 to 120 μm is continuously produced for 40 kg or more per hour, the maximum rotation speed of the pin hammer rotor and the maximum rotation speed of the classification rotor are set. The above range is preferable.
In pulverization by an impact type pulverizer that incorporates an airflow classification mechanism and uses a pin hammer, the rotation of the pin hammer rotor preferably has a lower limit of about 4000 rpm or more. More preferably, the rotational speed of the pin hammer rotor is about 6000 to 9000 rpm. Furthermore, the lower limit of the rotational speed of the classification rotor is preferably about 2000 rpm or more. The rotation speed of the classification rotor is more preferably about 2000 to 5000 rpm.
気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機による粉砕を行う際の温度は、例えば、0〜50℃程度で粉砕を行うことが好ましく、10〜40℃程度で粉砕を行うことがより好ましい。 The temperature at the time of pulverization by an impact pulverizer using a pin hammer with a built-in airflow classification mechanism is preferably, for example, pulverization at about 0 to 50 ° C., and more preferably at about 10 to 40 ° C. preferable.
ロキソプロフェンナトリウム二水和物の結晶及び結晶性の粉末の気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、例えばパルベライザ型粉砕機への投入量もしくは時間当たりの供給速度は、供給機の回転数を調節することで適宜設定すればよい。ロキソプロフェンナトリウム二水和物の微粉末を連続して作製する場合には、原料であるロキソプロフェンナトリウム二水和物の結晶又は結晶性の粉末を連続して気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機、例えばパルベライザ型粉砕機に供給することが好ましい。 Loxoprofen sodium dihydrate crystals and crystalline powder airflow classification mechanism built-in, impact type mill using pin hammer, for example, supply rate to the pulverizer type mill, or supply rate per hour is determined by rotation of the feeder What is necessary is just to set suitably by adjusting a number. When preparing loxoprofen sodium dihydrate fine powder continuously, the loxoprofen sodium dihydrate crystal or crystalline powder, which is the raw material, has a built-in airflow classification mechanism and impact using a pin hammer It is preferable to supply to a type pulverizer, for example, a pulverizer type pulverizer.
本発明によれば、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約20〜120μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末を連続して製造することができる。 According to the present invention, when measuring with a laser diffraction particle size distribution meter, a fine powder of loxoprofen sodium dihydrate having a volume average particle size in the range of about 20 to 120 μm can be continuously produced.
本発明の製造方法は、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約20〜120μmの範囲の粒子であるロキソプロフェンナトリウム二水和物の微粉末の製造に好適に使用される。
すなわち本発明の製造方法によれば、このようなロキソプロフェンナトリウム二水和物の微粉末を高い生産性で連続して製造することができる。より好ましい態様においては、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約40〜90μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末を連続して製造することができる。すなわち本発明の製造方法は、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約40〜90μmの範囲にあるロキソプロフェンナトリウム二水和物の微粉末の製造方法として特に好適である。The production method of the present invention is suitably used for the production of fine powder of loxoprofen sodium dihydrate which is a particle having a volume average particle diameter in the range of about 20 to 120 μm when measured by a laser diffraction particle size distribution analyzer. .
That is, according to the production method of the present invention, such fine powder of loxoprofen sodium dihydrate can be produced continuously with high productivity. In a more preferred embodiment, a fine powder of loxoprofen sodium dihydrate having a volume average particle diameter in the range of about 40 to 90 μm can be continuously produced as measured by a laser diffraction particle size distribution analyzer. That is, the production method of the present invention is particularly suitable as a method for producing fine powder of loxoprofen sodium dihydrate having a volume average particle diameter in the range of about 40 to 90 μm when measured with a laser diffraction particle size distribution analyzer.
本発明の好ましい実施態様の1例として、レーザー回折式粒度分布計で測定するとき、体積平均粒子径が約20〜120μm(好ましくは体積平均粒子径が約40〜90μm)の範囲にあるロキソプロフェンナトリウム二水和物の微粉末を、一時間当たり約40Kg以上連続して作製することが挙げられる。本発明によれば、このようなロキソプロフェンナトリウム二水和物の微粉末を、一時間当たり約40Kg以上の生産性で、通常、1回につき約5時間程度は連続して製造することができる。好ましくは、1回につき1〜3時間程度連続して製造する。 As an example of a preferred embodiment of the present invention, loxoprofen sodium having a volume average particle diameter of about 20 to 120 μm (preferably a volume average particle diameter of about 40 to 90 μm) as measured by a laser diffraction particle size distribution meter. It is mentioned that a dihydrate fine powder is continuously produced for about 40 kg or more per hour. According to the present invention, such a fine powder of loxoprofen sodium dihydrate can be produced continuously at a productivity of about 40 kg or more per hour, usually for about 5 hours per time. Preferably, it is continuously produced for about 1 to 3 hours at a time.
本明細書中、特に断らない場合、「体積平均粒子径」は、レーザー回折式粒度分布計で測定するときの体積平均粒子径である。 In the present specification, unless otherwise specified, the “volume average particle diameter” is a volume average particle diameter as measured by a laser diffraction particle size distribution meter.
本発明において体積平均粒子径の測定に用いられるレーザー回折式粒度分布計として、Sysmex社製の型番MASTERSIZER2000等が好適である。 As the laser diffraction particle size distribution meter used for measuring the volume average particle size in the present invention, model number MASTERSIZER2000 manufactured by Sysmex is suitable.
本発明の製造方法により得られるロキソプロフェンナトリウム二水和物の微粉末は、体積平均粒子径が約20〜120μmの範囲であり、そのまま医薬品製剤用微粉末として各種内服剤又は外用剤の製剤の製造に好適に用いることができるものである。本発明により製造される微粉末が好適に用いられる医薬品製剤として、例えば、錠剤等の内服剤;クリーム剤、軟膏剤等の塗布剤;プラスター剤、テープ剤、パッチ剤、パップ剤等の貼付剤等が挙げられる。ロキソプロフェンナトリウム二水和物の微粉末を用いる医薬品製剤の製造方法は特に限定されず、公知の方法を採用することができる。製剤の製造に用いられる賦形剤等も特に限定されず、公知のものを適宜選択して使用することができる。 The fine powder of loxoprofen sodium dihydrate obtained by the production method of the present invention has a volume average particle diameter in the range of about 20 to 120 μm, and can be used to produce various internal preparations or external preparations as fine powders for pharmaceutical preparations. Can be suitably used. Examples of pharmaceutical preparations in which the fine powder produced according to the present invention is suitably used include, for example, internal preparations such as tablets; coating agents such as creams and ointments; patches such as plasters, tapes, patches, and poultices Etc. The manufacturing method of the pharmaceutical formulation which uses the fine powder of loxoprofen sodium dihydrate is not specifically limited, A well-known method is employable. The excipient used for the preparation of the preparation is not particularly limited, and a known one can be appropriately selected and used.
以下、実施例を挙げて本発明をさらに詳しく説明するが、これらは本発明を何ら限定するものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in more detail, these do not limit this invention at all.
実施例1
気流分級機構を内蔵し、ピンハンマを用いる衝撃式粉砕機であるパルベライザ型粉砕機による粉砕。
ホソカワミクロン株式会社製ACMパルベライザ2EC(商品名)により、ロキソプロフェンナトリウム二水和物の結晶(米沢浜理薬品工業株式会社製)を粉砕した。Example 1
Pulverization by a pulverizer type pulverizer, which is an impact pulverizer that uses a pin hammer and incorporates an airflow classification mechanism.
Crystals of loxoprofen sodium dihydrate (manufactured by Yonezawa Hamari Chemical Co., Ltd.) were pulverized by ACM Pulverizer 2EC (trade name) manufactured by Hosokawa Micron Corporation.
テスト機:ACMパルベライザ2EC(商品名、ホソカワミクロン社製)
ピンハンマ粉砕ロータ:最大回転速度12,000rpm
分級ロータ:最大回転速度6,000rpm
ライナ:スムースライナ
分級ロータ:ショートタイプ
粉砕機中には冷風の通風をしなかった(室温約27℃)。Test machine: ACM Pulverizer 2EC (trade name, manufactured by Hosokawa Micron)
Pin hammer grinding rotor: Maximum rotation speed 12,000rpm
Classification rotor: Maximum rotation speed 6,000rpm
Liner: Smooth liner
Classification rotor: Short type Cold air was not passed through the pulverizer (room temperature: about 27 ° C.).
ACMパルベライザ2EC粉砕機による粉砕に使用したロキソプロフェンナトリウム二水和物の量(使用粉体量)は、試験1回目(Run. No. 001)は、0.7kg、試験2回目(Run. No. 002)は、50kgであった。 The amount of loxoprofen sodium dihydrate used for pulverization with the ACM Pulverizer 2EC pulverizer (the amount of powder used) was 0.7 kg for the first test (Run. No. 001) and the second test (Run. No.). 002) was 50 kg.
粉砕条件は、試験1回目(Run. No. 001)では、粉砕ロータ回転数を7500rpmに設定し、分級ロータ回転数を3000rpmに設定した。また、この条件で、0.7kgのロキソプロフェンナトリウム二水和物を使用して、1時間あたりの粉体供給量を46.7kgに設定してロキソプロフェンナトリウム二水和物の微粉末を製造した。 As for the grinding conditions, in the first test (Run. No. 001), the rotational speed of the grinding rotor was set to 7500 rpm, and the rotational speed of the classification rotor was set to 3000 rpm. Under these conditions, 0.7 kg of loxoprofen sodium dihydrate was used, and the powder supply amount per hour was set to 46.7 kg to produce fine powder of loxoprofen sodium dihydrate.
試験2回目(Run. No. 002)では、粉砕ロータ回転数を8500rpmに設定し、分級ローター回転数を3000rpmに設定した。また、この条件で、50kgのロキソプロフェンナトリウム二水和物を使用して、供給機による1時間あたりの粉体供給量を46.7kgに設定してロキソプロフェンナトリウム二水和物の微粉末を製造した。 In the second test (Run. No. 002), the rotational speed of the grinding rotor was set to 8500 rpm, and the rotational speed of the classification rotor was set to 3000 rpm. Under these conditions, 50 kg of loxoprofen sodium dihydrate was used, and a fine powder of loxoprofen sodium dihydrate was produced by setting the powder supply amount per hour by the feeder to 46.7 kg. .
粉砕前のロキソプロフェンナトリウム二水和物の結晶の体積基準メジアン径及び体積平均粒子径、並びにACMパルベライザ2EC粉砕機による粉砕により得られた微粉末の体積基準メジアン径及び体積平均粒子径を、Sysmex社製レーザー回折式粒度分布計MASTERSIZER2000(型番)により測定した。また、得られたロキソプロフェンナトリウム二水和物の結晶の微粉末の粗比容及び充比容を、日本薬局方に記載の方法に従って測定した。 The volume-based median diameter and volume-average particle diameter of loxoprofen sodium dihydrate crystals before pulverization, and the volume-based median diameter and volume-average particle diameter of fine powder obtained by pulverization using an ACM Pulverizer 2EC pulverizer were measured by Sysmex. It was measured with a laser diffraction type particle size distribution meter MASTERSIZER2000 (model number). Further, the crude specific volume and the full specific volume of the fine powder of loxoprofen sodium dihydrate obtained were measured according to the method described in the Japanese Pharmacopoeia.
結果を表2に示す。表2中、「100μm pass」とは、100μmの目の粗さの篩いにかけたとき、全体の何%が通過するかを示している。
表2から、粉砕ロータ回転数及び分級ロータ回転数をほぼ一定に設定すると、体積平均粒子径、粒度分布、処理量、及び比容につき再現性が得られた。また、試験1回目(Run. No. 001)及び試験2回目(Run. No. 002)のいずれにおいても、テスト期間中微粉末の付着・固着による粉砕機の閉塞はみられなかった。室温は約27℃であったが、粉砕中に顕著な発熱はなく特段の冷却操作は必要なかった。これは微粉末の粉砕機内部への付着・固着による滞留がなかったためであると考えられる。使用したテスト機は分級ユニットを内蔵しているので、粒子は過粉砕されず粉砕品の粒度分布が他機粉砕品に比べてシャープになった。分級ユニットを内蔵しているため前処理粉砕の必要はなく、粉砕品についてもさらに篩過する必要がなかった。したがって、生産性が大幅に改善された。ランニングコストがピンミル粉砕機やジェットミル粉砕機に比べて最も安価であると考えられた。以上より、ACMパルベライザ2ECを用いるとロキソプロフェンナトリウム二水和物の微粉末の連続生産が可能であることが判明した。The results are shown in Table 2. In Table 2, “100 μm pass” indicates what percentage of the whole passes through a sieve having a coarseness of 100 μm.
From Table 2, when the pulverization rotor rotation speed and the classification rotor rotation speed were set almost constant, reproducibility was obtained with respect to the volume average particle diameter, particle size distribution, throughput, and specific volume. Further, in both the first test (Run. No. 001) and the second test (Run. No. 002), the crusher was not clogged due to adhesion and adhesion of fine powder during the test period. Although the room temperature was about 27 ° C., there was no remarkable heat generation during the pulverization, and no special cooling operation was required. This is presumably because there was no retention of fine powder due to adhesion and sticking inside the pulverizer. Since the test machine used has a built-in classification unit, the particles are not excessively pulverized and the particle size distribution of the pulverized product is sharper than those of other machine pulverized products. Since the classification unit is built in, pre-treatment pulverization is not necessary, and the pulverized product does not need to be further sieved. Therefore, productivity has been greatly improved. The running cost was considered to be the cheapest compared with the pin mill and jet mill. From the above, it was found that the use of ACM pulverizer 2EC enables continuous production of fine powder of loxoprofen sodium dihydrate.
比較例1
ピンミル粉砕
ロキソプロフェンナトリウム二水和物の結晶(米沢浜理薬品工業株式会社製)を、以下のテスト機(ピンミル粉砕機)を用いて粉砕した。
テスト機:ファインインパクトミルUPZ160(商品名、ホソカワミクロン株式会社製)Comparative Example 1
Pin mill pulverization Crystals of loxoprofen sodium dihydrate (manufactured by Yonezawa Hamari Chemical Co., Ltd.) were pulverized using the following test machine (pin mill pulverizer).
Test machine: Fine impact mill UPZ160 (trade name, manufactured by Hosokawa Micron Corporation)
試験は、試験3〜5(Run. No. 003〜Run. No. 005)の3回行った。
各試験において粉砕に用いたロキソプロフェンナトリウム二水和物の結晶の使用量(使用粉体量)、ピンディスクの使用状況、回転数、及び得られた微粒子の体積平均粒子径を、表3に示す。体積平均粒子径及び体積基準におけるメジアン径(D50)の測定に用いた機器は、実施例1と同じレーザー回折式粒度分布計(Sysmex社製、型番MASTERSIZER2000)である。The test was performed three times, tests 3 to 5 (Run. No. 003 to Run. No. 005).
Table 3 shows the amount of loxoprofen sodium dihydrate crystals used for grinding in each test (the amount of powder used), the state of use of the pin disk, the number of rotations, and the volume average particle size of the fine particles obtained. . The apparatus used for the measurement of the volume average particle diameter and the median diameter (D50) on the volume basis is the same laser diffraction particle size distribution analyzer (model number MASTERSIZER2000, manufactured by Sysmex) as in Example 1.
ピンミルによる粉砕では、ピンに粉砕物が付着・固着しそれが成長することでピン間隔が序々に狭くなり、短時間で閉塞に至り、発熱により結晶が融解し粉砕不能になった。本化合物(ロキソプロフェンナトリウム二水和物)は結晶水を有する二水和物であり、示差熱分析の結果から約58〜77℃で脱水が起きることが分かっている。本粉砕機では付着又は固着による閉塞・発熱により結晶水が外れることが考えられる。 In the pulverization by the pin mill, the pulverized material adheres and adheres to the pin and grows, so that the interval between the pins is gradually narrowed and closes in a short time. This compound (loxoprofen sodium dihydrate) is a dihydrate having water of crystallization, and the results of differential thermal analysis show that dehydration occurs at about 58-77 ° C. In this pulverizer, it is conceivable that crystal water comes off due to clogging and heat generation due to adhesion or sticking.
ピンディスクのピンを間引くことで、ピン間隔を広げても同じ現象がみられた。ピン数を減らしすぎると求める粒度まで粉砕することができなかった。生産能力、製品の均一性において問題があると判断した。 The same phenomenon was observed even if the pin spacing was increased by thinning the pins of the pin disc. If the number of pins was reduced too much, the desired particle size could not be pulverized. It was judged that there was a problem in production capacity and product uniformity.
ハンマをプレートビータ(プレート状ハンマ)に換えて検討したが、満足な結果は得られなかった(Run. No. RUN-1、Run. No.RUN-4及びRun. No.RUN-6)。この結果を表4に示す。 Although the hammer was replaced with a plate beater (plate-shaped hammer), satisfactory results were not obtained (Run. No. RUN-1, Run. No. RUN-4 and Run. No. RUN-6). The results are shown in Table 4.
比較例2
ジェットミル粉砕
ロキソプロフェンナトリウム二水和物の結晶(米沢浜理薬品工業株式会社製)を、以下のテスト機(ジェットミル粉砕機)を用いて粉砕した。
Comparative Example 2
Jet mill pulverization Loxoprofen sodium dihydrate crystals (manufactured by Yonezawa Hamari Chemical Co., Ltd.) were pulverized using the following test machine ( jet mill pulverizer).
試験は、試験7〜11(Run. No. 006〜Run. No. 0010)の5回行った。
各試験において粉砕に用いたロキソプロフェンナトリウム二水和物の結晶の使用量(使用粉体量)、粉砕条件、及び得られた微粒子の体積平均粒子径を、表5に示す。体積平均粒子径の測定に用いた機器は、実施例1と同じレーザー回折式粒度分布計(Sysmex社製、型番MASTERSIZER2000)である。The test was performed five times of Tests 7 to 11 (Run. No. 006 to Run. No. 0010).
Table 5 shows the amount of the loxoprofen sodium dihydrate crystals used for grinding in each test (the amount of powder used), the grinding conditions, and the volume average particle diameter of the fine particles obtained. The apparatus used for the measurement of the volume average particle diameter is the same laser diffraction type particle size distribution analyzer as in Example 1 (manufactured by Sysmex, model number MASTERSIZER2000).
ジェットミルを用いる粉砕では、粉砕圧を最低レベルまで落とすことで粉砕は可能であったが、平均粒径が細かくなりすぎ比容積が大きくなり製剤に適さない微粉末が得られた。本機の構造上 粉砕する前にカッターミル等の解砕機で前処理粉砕をしないと供給ノズルが閉塞した。また処理量が大きくなると、バグフィルタ等の設備投資が大きくなると考えられた。本機はコンプレッサーを使用するため電力コストも相対的に大きく商業生産には不利であると考えられた。 In pulverization using a jet mill, pulverization was possible by lowering the pulverization pressure to the lowest level, but the average particle size became too fine and the specific volume increased, resulting in a fine powder unsuitable for the preparation. Due to the structure of this machine, the feed nozzle was blocked if it was not pre-processed by a crusher such as a cutter mill before crushing. Moreover, it was thought that the capital investment of bug filters and the like increased as the amount of processing increased. Since this machine uses a compressor, the power cost is relatively high and it is considered disadvantageous for commercial production.
製剤例1(錠剤の製造)
(1)実施例1で製造したロキソプロフェンナトリウム二水和物の微粉末 112g
(2)ヒドロキシプロピルセルロース 100g
(3)結晶セルロース 2400g
(4)カルメロースカルシウム 400g
(5)ステアリン酸マグネシウム 40g
(1)〜(4)を水で練合し、真空乾燥後、整粒を行う。この整粒末に(5)を混合し、打錠機により打錠する。この方法により、1錠あたり250mgでロキソプロフェンナトリウム二水和物70mgを含有する錠剤1600錠を得る。Formulation Example 1 (Manufacture of tablets)
(1) 112 g of fine powder of loxoprofen sodium dihydrate produced in Example 1
(2) Hydroxypropylcellulose 100g
(3) 2400 g of crystalline cellulose
(4) Carmellose calcium 400g
(5) Magnesium stearate 40g
(1) to (4) are kneaded with water, dried in vacuum, and then sized. (5) is mixed with this sized powder and tableted with a tableting machine. By this method, 1600 tablets containing 250 mg of loxoprofen sodium dihydrate at 250 mg per tablet are obtained.
製剤例2(貼付製剤用粘着剤の製造)
(1)実施例1で製造したロキソプロフェンナトリウム二水和物の微粉末 18g
(2)スチレン−イソプレン−スチレンブロック共重合体 100g
(3)脂環族飽和炭化水素樹脂 120g
(4)流動パラフィン 240g
(2)〜(4)を混合した後、(1)の実施例1で製造したロキソプロフェンナトリウム二水和物の微粉末を添加混合し均一な粘着剤を得る。Formulation Example 2 (Manufacture of adhesive for patch preparation)
(1) Fine powder of loxoprofen sodium dihydrate produced in Example 1 18 g
(2) Styrene-isoprene-styrene block copolymer 100 g
(3) 120 g of alicyclic saturated hydrocarbon resin
(4) Liquid paraffin 240g
After mixing (2) to (4), the fine powder of loxoprofen sodium dihydrate produced in Example 1 of (1) is added and mixed to obtain a uniform adhesive.
本発明は、医薬等の分野において有用である。 The present invention is useful in the field of medicine and the like.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013508833A JP5866342B2 (en) | 2011-04-07 | 2012-03-29 | Method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011085286 | 2011-04-07 | ||
JP2011085286 | 2011-04-07 | ||
JP2013508833A JP5866342B2 (en) | 2011-04-07 | 2012-03-29 | Method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate |
PCT/JP2012/058402 WO2012137667A1 (en) | 2011-04-07 | 2012-03-29 | Method for producing fine powder of loxoprofen sodium dihydrate for pharmaceutical preparations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2012137667A1 JPWO2012137667A1 (en) | 2014-07-28 |
JP5866342B2 true JP5866342B2 (en) | 2016-02-17 |
Family
ID=46969068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013508833A Active JP5866342B2 (en) | 2011-04-07 | 2012-03-29 | Method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5866342B2 (en) |
KR (1) | KR101812697B1 (en) |
CN (1) | CN103533931B (en) |
WO (1) | WO2012137667A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106619492A (en) * | 2017-03-10 | 2017-05-10 | 广州奥博医药科技有限公司 | Precursor type non-steroid anti-inflammatory eye ointment and preparation method thereof |
CN108863765B (en) * | 2018-08-07 | 2021-04-13 | 迪嘉药业集团有限公司 | Preparation method of loxoprofen sodium crystal |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6271552A (en) * | 1985-09-24 | 1987-04-02 | 武田薬品工業株式会社 | Fine granulation of organic compound |
JPH1121236A (en) * | 1997-07-01 | 1999-01-26 | Ohara Yakuhin Kogyo Kk | Loxoprofen-sodium solid preparation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2042162B1 (en) * | 2006-07-19 | 2017-10-04 | Asahi Kasei Kabushiki Kaisha | Process for producing spherical elementary granule containing readily water-soluble drug |
CN101342147A (en) * | 2008-08-28 | 2009-01-14 | 复旦大学 | Loxoprofen sodium framework tablet |
-
2012
- 2012-03-29 CN CN201280017392.1A patent/CN103533931B/en active Active
- 2012-03-29 WO PCT/JP2012/058402 patent/WO2012137667A1/en active Application Filing
- 2012-03-29 KR KR1020137029610A patent/KR101812697B1/en active IP Right Grant
- 2012-03-29 JP JP2013508833A patent/JP5866342B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6271552A (en) * | 1985-09-24 | 1987-04-02 | 武田薬品工業株式会社 | Fine granulation of organic compound |
JPH1121236A (en) * | 1997-07-01 | 1999-01-26 | Ohara Yakuhin Kogyo Kk | Loxoprofen-sodium solid preparation |
Non-Patent Citations (1)
Title |
---|
JPN6012026442; '3.9.ACMパルベライザ' 先端粉砕技術と応用 , 2005, pp.159-161, (有)エヌジーティー * |
Also Published As
Publication number | Publication date |
---|---|
WO2012137667A1 (en) | 2012-10-11 |
KR20140032400A (en) | 2014-03-14 |
KR101812697B1 (en) | 2017-12-27 |
CN103533931A (en) | 2014-01-22 |
CN103533931B (en) | 2016-08-17 |
JPWO2012137667A1 (en) | 2014-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kaialy et al. | Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler | |
JP6966780B2 (en) | Manufacturing method of acetaminophen preparation | |
JP2014510184A (en) | Method for producing cellulose derivative having high bulk density and good fluidity | |
BRPI0809282A2 (en) | '' GRANULAR MATERIAL, DETERMINATION FOR A DOSAGE FORM, DOSAGE FORM, DIRECT COMPRESSION PROCESS FOR PREPARING A DOSAGE FORM, USE OF GRANULAR MATERIAL AND PROCESS FOR GRANULATING A POLYMER POWDER '' | |
KR20140147891A (en) | Aggregate particles | |
JP6203182B2 (en) | (S) -Ethyl 2-amino-3- (4- (2-amino-6-((R) -1- (4-chloro-2- (3-methyl-1H-pyrazol-1-yl) phenyl) -2,2,2-trifluoroethoxy) pyrimidin-4-yl) phenyl) propanoate solid agent | |
JP5866342B2 (en) | Method for producing fine powder for pharmaceutical preparation of loxoprofen sodium dihydrate | |
TW201124157A (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
CN112351772B (en) | Method for treating bulk drug particles with inconsistent particle sizes | |
WO2019093434A1 (en) | Acetaminophen preparation, and method for producing same | |
HU226221B1 (en) | Milling process for the production of finely milled medicinal substances | |
CN103025315B (en) | Control the method that active component discharges from dosage form | |
JPWO2008143239A1 (en) | Crystalline finely divided particles | |
KR20190027844A (en) | Inhalable medicinal composition | |
JP2018177800A (en) | Production method of premix drug substance | |
Rose | Engineering composite particles to overcome the poor pharmaceutical performance of paracetamol | |
JP6538501B2 (en) | Industrial Production Method of Crystalline Form E Minodronic Acid Hydrate | |
CN114105839A (en) | Pretreatment method of bulk drug and composition thereof | |
EP3216463A1 (en) | Solid preparation containing alkyl cellulose and method for producing the same | |
JP2005538038A (en) | Powder composition comprising zaleplon having a defined particle size distribution and pharmaceutical product made therefrom | |
JP2015155379A (en) | Inhalation powder and production method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150319 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160104 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5866342 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |